Home » Stocks » SGMO

Sangamo Therapeutics, Inc. (SGMO)

Stock Price: $11.49 USD 0.30 (2.68%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
After-hours: $11.45 -0.04 (-0.35%) Feb 26, 7:58 PM
Market Cap 1.65B
Revenue (ttm) 118.19M
Net Income (ttm) -121.00M
Shares Out 134.45M
EPS (ttm) -0.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $11.49
Previous Close $11.19
Change ($) 0.30
Change (%) 2.68%
Day's Open 11.30
Day's Range 11.19 - 11.78
Day's Volume 3,345,489
52-Week Range 4.81 - 19.43

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 3 days ago

Sangamo (SGMO) delivered earnings and revenue surprises of -61.11% and -31.44%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 3 days ago

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported fourth quarter and full year 2020 financial results and recent business...

Business Wire - 1 week ago

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in the following investor confer...

Business Wire - 1 week ago

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its fourth quarter and f...

Business Wire - 3 weeks ago

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Rob Schott, MD, MPH, FACC, as Senior Vice President...

InvestorPlace - 1 month ago

Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. The post 7 CRISPR Stocks for the Future of Medicine appeared f...

Other stocks mentioned: BEAM, CLLS, CLXT, CRSP, EDIT, NTLA
Business Wire - 1 month ago

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Chief Financial Officer Sung Lee is leaving the Company to pursue...

Business Wire - 1 month ago

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present a corporate overview at the 39th Annual J...

Seeking Alpha - 2 months ago

Sangamo: 'Good Companies Get Bought, Not Sold'

Zacks Investment Research - 2 months ago

Sangamo Therapeutics (SGMO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Zacks Investment Research - 2 months ago

Investors need to pay close attention to Sangamo Therapeutics (SGMO) stock based on the movements in the options market lately.

Zacks Investment Research - 2 months ago

In the Century of Biology, it pays to own the future of curing disease at the root.

Other stocks mentioned: CRSP, EDIT, NTLA, VRTX
Business Wire - 2 months ago

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from th...

Other stocks mentioned: PFE
Seeking Alpha - 3 months ago

Gene regulation targeted at RNA or DNA has enormous potential for previously intractable nervous system disorders. Allele-specific gene regulation is a more precise approach targeting only the...

Business Wire - 3 months ago

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences: 29...

Seeking Alpha - 3 months ago

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

Sangamo (SGMO) delivered earnings and revenue surprises of 95.83% and 101.79%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 3 months ago

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported third quarter 2020 financial results and recent business highlights. “W...

Business Wire - 3 months ago

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its third quarter 2020 f...

Zacks Investment Research - 3 months ago

Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 4 months ago

NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that the first participant has...

Other stocks mentioned: PFE
Seeking Alpha - 4 months ago

Sangamo Therapeutic, Inc. (NASDAQ: SGMO) is a clinical-stage biotech focused on genomic medicines using proprietary platform technologies covering gene therapy, ex-vivo gene-edited cell therap...

Business Wire - 5 months ago

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc.

Investors Business Daily - 5 months ago

A Relative Strength Rating upgrade for Sangamo Therapeutics shows improving technical performance. Will it continue?

Zacks Investment Research - 5 months ago

Gene editing will dramatically transform medicine and life, so should you just buy-and-hold the stocks?

Other stocks mentioned: CRSP, EDIT, NTLA, VRTX
Investors Business Daily - 6 months ago

A Relative Strength Rating upgrade for Sangamo Therapeutics shows improving technical performance. The post Stocks With Rising Relative Price Strength: Sangamo Therapeutics appeared first on I...

Business Wire - 6 months ago

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc.

Seeking Alpha - 6 months ago

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Sangamo (SGMO) delivered earnings and revenue surprises of -163.41% and -71.07%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 6 months ago

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc.

Business Wire - 6 months ago

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc.

Business Wire - 6 months ago

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc.

Zacks Investment Research - 6 months ago

Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 7 months ago

The Biogen collaboration was completed in 2Q. Cash is now expected to fund operations beyond BLA timing for Hemophilia A.

The Motley Fool - 7 months ago

These three stocks are positioned for growth -- but investors must tread carefully in the short term.

Other stocks mentioned: EDIT, MRNA
Business Wire - 8 months ago

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced changes to its research and development organization. Going forward, research and development will ...

The Motley Fool - 8 months ago

While the data looks good so far, the duo's treatment is behind a similar BioMarin therapy in the testing and approval process.

Other stocks mentioned: PFE
Zacks Investment Research - 8 months ago

Investors need to pay close attention to Sangamo (SGMO) stock based on the movements in the options market lately.

The Motley Fool - 8 months ago

Each company aims to use its genome editing platform to treat disease, but which has an edge?

Other stocks mentioned: CRSP
Investors Business Daily - 8 months ago

Shares of Sangamo Therapeutics surged Thursday ahead of an update next week for its Pfizer-partnered gene therapy in hemophilia A. SGMO stock popped in high volume.

Seeking Alpha - 9 months ago

Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

Sangamo (SGMO) delivered earnings and revenue surprises of -60.87% and -57.78%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 9 months ago

Is (SGMO) Outperforming Other Medical Stocks This Year?

The Motley Fool - 9 months ago

Which stock wins in a battle between these two clinical-stage biotechs?

Other stocks mentioned: CARA
Zacks Investment Research - 10 months ago

How to Find Strong Stocks Under $10 to Buy During the Market Comeback

Other stocks mentioned: CWH, GFI, MAT, DHT
The Motley Fool - 10 months ago

Which of these two gene-editing companies is the better investment?

Other stocks mentioned: EDIT
The Motley Fool - 10 months ago

With the coronavirus pandemic on everyone's mind, these three promising stocks have stayed under the radar.

Other stocks mentioned: KGC, PTON
Seeking Alpha - 11 months ago

Sangamo Therapeutics: Market Cap Is At A Bargain Relative To Its Cash Position

Seeking Alpha - 11 months ago

Sangamo's Partnership With Biogen Is Only One Big Pharma Partnership Based Off Of Pipeline

Other stocks mentioned: BIIB
Seeking Alpha - 11 months ago

Sangamo: Adding Another Partnership To The Bull Thesis

About SGMO

Sangamo Therapeutics, a biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression. I... [Read more...]

Industry
Biotechnology
IPO Date
Apr 6, 2000
CEO
Alexander Macrae
Employees
413
Stock Exchange
NASDAQ
Ticker Symbol
SGMO
Full Company Profile

Financial Performance

In 2020, SGMO's revenue was $118.19 million, an increase of 15.39% compared to the previous year's $102.43 million. Losses were -$121.00 million, 27.1% more than in 2019.

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for SGMO stock is "Buy." The 12-month stock price forecast is 20.60, which is an increase of 79.29% from the latest price.

Price Target
$20.60
(79.29% upside)
Analyst Consensus: Buy